Simonetti Alessio, Restaino Antonio, Bernardi Evelina, Ferrara Ottavia Marianna, Margoni Stella, D'Onofrio Antonio Maria, Ranieri Federica, Janiri Delfina, Galluzzo Vincenzo, Tosato Matteo, Kotzalidis Georgios D, Landi Francesco, Sani Gabriele
Department of Neuroscience, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 1977 Butler Blvd., Houston, TX 77030, USA.
Brain Sci. 2024 Jan 3;14(1):47. doi: 10.3390/brainsci14010047.
Interleukin 6 (IL-6) receptor inhibitors tocilizumab and sarilumab have recently been approved for severe coronavirus disease 2019 (COVID-19). They also affect mood, even though their effect on the post-COVID-19 syndrome-related psychopathology still has to be investigated. The aim of this study was to investigate their effect on psychopathology in a sample of patients with post-COVID-19 syndrome. We included 246 patients (34% female, 66% male) aged 18-75 years who had been hospitalized for COVID. Patients were split into those who received anti-IL-6 receptor agents (Anti-IL-6-R, = 88) and those who did not (Ctrl, = 158). The former group was further split into those receiving tocilizumab (TOC, = 67) and those receiving sarilumab (SAR, = 21). Groups were compared based on clinical characteristics before and during COVID-19 as well as on physical and psychiatric symptoms after COVID-19. Ctrl had less psychiatric and physical symptoms during hospitalization and more post-COVID-19 diarrhea, headache, cough, and dyspnea upon exertion than those receiving IL-6-receptor inhibitors. Ctrl also showed greater difficulties in emotion regulation. These differences were driven by TOC vs. Ctrl, whereas differences between SAR and Ctrl or TOC did not reach significance. IL-6 receptor inhibitors are related to a lower post-COVID-19 illness burden and seem to be effective in emotion regulation. Further research is needed to confirm these findings.
白细胞介素6（IL-6）受体抑制剂托珠单抗和萨瑞鲁单抗最近已被批准用于治疗严重的2019冠状病毒病（COVID-19）。它们也会影响情绪，尽管它们对COVID-19后综合征相关精神病理学的影响仍有待研究。本研究的目的是调查它们对COVID-19后综合征患者样本中精神病理学的影响。我们纳入了246名年龄在18至75岁之间因COVID住院的患者（女性34%，男性66%）。患者被分为接受抗IL-6受体药物的患者（抗IL-6-R组，n = 88）和未接受抗IL-6受体药物的患者（对照组，n = 158）。前一组进一步分为接受托珠单抗的患者（TOC组，n = 67）和接受萨瑞鲁单抗的患者（SAR组，n = 21）。根据COVID-19之前和期间的临床特征以及COVID-19之后的身体和精神症状对各组进行比较。对照组在住院期间的精神和身体症状较少，但在COVID-19后出现腹泻、头痛、咳嗽和运动时呼吸困难的情况比接受IL-6受体抑制剂的患者更多。对照组在情绪调节方面也表现出更大的困难。这些差异是由TOC组与对照组之间的差异驱动的，而SAR组与对照组或TOC组之间的差异未达到显著水平。IL-6受体抑制剂与较低的COVID-19后疾病负担相关，并且似乎在情绪调节方面有效。需要进一步的研究来证实这些发现。
